FOXOD · Foxo Technologies Inc.
$0.03
-0.01 (-21.36%)
At close · Jul 28
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“until additional equity or debt capital is secured and the Company begins generating sufficient revenue and operating cash flows, there is substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$42,616
Shares
1.42M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$16.37M
+304%
FY2025
Net Income
-$12.43M
-0.2%
FY2025
Gross Margin
8.95%
-23.7pp
FY2023
Operating Margin
-63.11%
+128.5pp
FY2025
Operating Cash Flow
-$3.87M
-36.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $18.37M | $16.37M | $4.05M | $145.29K | $511K | $120K | — | |
| — | — | — | $132K | $344K | $120K | — | |
| — | — | — | $13K | $167K | $120K | — | |
| — | — | — | 8.95% | 32.68% | 100% | — | |
| $188.05K | $182.5K | $312.27K | $900.43K | $3.05M | $4.88M | — | |
| $5.24M | — | — | — | — | — | $1.15M | |
| $11.47M | $11.36M | $7.23M | $19.4M | $25.83M | $10.27M | — | |
| $50.73K | $31.99K | $1M | $1.3M | $1.28M | — | — | |
| — | $597.43K | $1.24M | $1.28M | $1.49M | — | — | |
| $27.42M | $26.7M | $11.81M | $22.33M | $40.33M | $15.15M | — | |
| -$9.06M | -$10.33M | -$7.76M | -$22.19M | -$40.17M | -$15.03M | -$1.15M | |
| — | -63.11% | -191.58% | -15271.16% | -7860.47% | -12525.83% | — | |
| — | -$9.73M | -$6.53M | -$20.91M | -$38.68M | — | — | |
| — | — | — | — | $1.44M | $1.12M | — | |
| $186.11K | — | — | — | — | $32K | $1585 | |
| -$4.41M | -$2.3M | -$4.66M | -$4.26M | -$55.09M | -$236K | — | |
| -$13.46M | -$12.63M | -$12.42M | -$26.45M | — | — | — | |
| — | -$182.83K | — | — | — | — | — | |
| -$13.27M | -$12.43M | -$12.41M | -$26.45M | -$95.26M | -$38.49M | -$1.78M | |
| — | -75.95% | -306.21% | -18205.21% | -18640.9% | -32073.33% | — | |
| -$15.6K | -$16.74K | -$14.57K | — | — | — | — | |
| -$35.67M | -$35.04M | -$13.56M | -$29.83M | -$95.26M | -$38.49M | -$1.78M | |
| shares | — | — | — | — | — | — | 9.5376 |
| shares | — | — | — | — | — | — | 9.5376 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Care Facilities median 1.28×
EV/EBIT
—
Medical Care Facilities median 19.28×
P/E (TTM)
—
Medical Care Facilities median 15.43×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Health Cares | $16,086,099 | $4,018,961 | — | — |
| Life Science Services | $252,502 | — | — | — |
| Corporate And Other | $15,093 | — | — | — |
| Labs | $13,923 | $32,640 | — | — |
| Labs and Life | — | — | $145,291 | — |
| All Other Segments | — | — | — | $511,000 |
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| Epigenetic Biomarker Services | $99,000 | $400,000 |
| Epigenetic Biomarker Royalties | $27,000 | $83,000 |
| Life Insurance Commissions | $19,000 | $28,000 |